Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer
| Autor: | Richard Bihrle, John P. Donohue, Lawrence H. Einhorn, Stephen D.W. Beck, Richard S. Foster |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Indiana medicine.medical_specialty Urology medicine.medical_treatment Population Retroperitoneal lymph node dissection Internal medicine Biomarkers Tumor medicine Humans education Contraindication Testicular cancer Survival analysis Neoplasm Staging Retrospective Studies Cisplatin Chemotherapy education.field_of_study business.industry Patient Selection Neoplasms Germ Cell and Embryonal Prognosis medicine.disease Survival Analysis Surgery Treatment Outcome Chemotherapy Adjuvant Lymph Node Excision Lymphadenectomy Lymph Nodes business medicine.drug |
| Zdroj: | Urologic Oncology: Seminars and Original Investigations. 23:423-430 |
| ISSN: | 1078-1439 |
| DOI: | 10.1016/j.urolonc.2005.06.007 |
| Popis: | Increased serum tumor markers after cisplatin-based chemotherapy have usually been considered a contraindication to surgery because of the presence of persistent active germ cell elements. However, a select population of patients with elevated serum tumor markers have undergone post-chemotherapy retroperitoneal lymph node dissection (RPLND) with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Long-term survival was observed in 50% of patients. Residual germ cell cancer was identified in 50% of patients, with a third alive at 5 years with no observed benefit from adjuvant chemotherapy. Select patients with increased tumor markers after chemotherapy are cured with surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect